Recipharm, Medspray, and Resyca enter into exclusive license agreement to develop nasally-delivered drug products using proprietary soft mist technology
Partnership will help bring breakthroughs in the nasal delivery of fragile biologics and small molecules to marketRecipharm, a leading contract development and manufacturing organisation (CDMO) is pleased to announce an exclusive licence and collaboration agreement with Medspray and Resyca, to develop soft mist nasal delivery devices for single and combination drug products. This collaboration extends the successful partnership between Recipharm and Medspray which resulted in the joint venture, Resyca; a company which is developing soft mist inhalers utilising Medspray’s nozzle